REMEGEN

🇭🇰Hong Kong, China

Country: 🇭🇰Hong Kong, China

Ownership: Public

Established: 2008-07-04

Employees: 3.4K

Market Cap: -

Website: http://www.remegen.com

Introduction: The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology. The company is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has been focusing on therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and double antibodies. Main products: tetacip, vidicetumab, RC28, RC88, RC98, RC108, RC118, RC148, RC198, etc.

Clinical Trials

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

Phase 2

Recruiting

Conditions: NMIBC

Interventions: Drug: RC48-ADC in Combination with gemcitabine

First Posted Date: 2023-07-13

Last Posted Date: 2023-07-13

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 85

Registration Number: NCT05943379

Locations: 🇨🇳
Peking University First Hosptital, Beijing, Beijing, China

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: Disitamab vedotin

First Posted Date: 2023-07-11

Last Posted Date: 2023-11-27

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT05940896

Locations: 🇨🇳
Shandong Cancer hospital &Institute, Jinan, Shandong, China

Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema

Phase 3

Recruiting

Conditions: Diabetic Macular Edema

Interventions: Biological: RC-28E
Biological: Aflibercept

First Posted Date: 2023-06-02

Last Posted Date: 2023-09-05

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 316

Registration Number: NCT05885503

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Renal Cell Carcinoma
Non-small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Melanoma
Urothelial Carcinoma
Colorectal Carcinoma

Interventions: Drug: RC198 Injection

First Posted Date: 2023-05-19

Last Posted Date: 2024-08-16

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 48

Registration Number: NCT05867303

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
🇦🇺
Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia

and more 2 locations

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

Phase 1

Recruiting

Conditions: NSCLC

Interventions: Drug: RC108

First Posted Date: 2023-04-20

Last Posted Date: 2024-04-10

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 106

Registration Number: NCT05821933

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Phase 1

Recruiting

Conditions: Advanced Solid Tumours

Interventions: Drug: RC88
Drug: Sintilimab Injection

First Posted Date: 2023-04-07

Last Posted Date: 2024-04-30

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 82

Registration Number: NCT05804526

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

A Study of Telitacicept in Patients With Primary IgA Nephropathy

Phase 3

Recruiting

Conditions: Primary IgA Nephropathy

Interventions: Biological: Telitacicept
Drug: Placebo

First Posted Date: 2023-04-05

Last Posted Date: 2023-09-06

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 308

Registration Number: NCT05799287

Locations: 🇨🇳
Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Peking University Shougang Hospital, Beijing, Beijing, China

and more 98 locations

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Phase 1

Not yet recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: RC48-ADC
Drug: Pyrotinib

First Posted Date: 2023-02-27

Last Posted Date: 2023-11-27

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 26

Registration Number: NCT05745740

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

Study of Telitacicept in Generalized Myasthenia Gravis

Phase 3

Recruiting

Conditions: Myasthenia Gravis, Generalized

Interventions: Drug: Placebo
Biological: Telitacicept

First Posted Date: 2023-02-21

Last Posted Date: 2023-10-12

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT05737160

Locations: 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Henan Provincial People's Hospital, Zhengzhou, Henan, China

and more 48 locations

Efficacy and Safety of RC28-E Versus Aflibercept

Phase 3

Recruiting

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: RC28-E
Drug: Aflibercept

First Posted Date: 2023-02-14

Last Posted Date: 2023-08-31

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 432

Registration Number: NCT05727397

Locations: 🇨🇳
Beijing Hospital, Beijing, Beijing, China

Home Terms & Conditions Privacy Policy